journal article·2019-12-04

Pharmaceutical Cocrystals: Molecules, Crystals, Formulations, Medicines

Malaz A. E. Yousef, Venu R. Vangala

Crystal Growth & Design· Volume 19· Issue 12
Publisher page

Abstract

Cocrystals are long known yet recently applied molecular entities. In the past decade, a significant potential has been demonstrated by these novel solids in terms of modifying the physicochemical and pharmacokinetic properties of drugs. Thus far, publications have outlined various aspects of cocrystals at the molecular level concentrating on their design, growing techniques, and physicochemical characterizations. However, to take cocrystals from bench to bedside, they have to be incorporated into suitable formulations notwithstanding that the attention paid to cocrystal formulations is so diminutive. This is the first systematic review based exclusively on cocrystals formulation. In this contribution, the impact of cocrystals on essential pharmaceutical properties is glanced at before shining the spotlight on cocrystals formulation. The findings suggest that preformulation characteristics play a significant role, however, after which a number of approaches are desired in order to develop successful cocrystal formulations. It further highlights the main hurdles encountered with cocrystals formulation and other challenges to the transformation of cocrystals into viable medicines to have the full picture. There are marketed cocrystal products now, and it can be said it is only a matter of time before cocrystals are added to the main selection toolbox alongside salts for developing medicinal products.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Crystallography and molecular interactions · Crystallization and Solubility Studies · Energetic Materials and Combustion

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Centre for Pharmaceutical Engineering Science, School of Pharmacy and Medical Sciences, University of Bradford, Bradford BD7 1DP, United Kingdom

References (95)

Show source-provided references
1. 10.1039/C6CC02943D10.1039/C6CC02943D ↗
2. 10.1007/s10870-011-0147-y10.1007/s10870-011-0147-y ↗
3. 10.1039/C5CC08216A10.1039/C5CC08216A ↗
4. 10.1098/rspa.1933.014010.1098/rspa.1933.0140 ↗
5. 10.1039/C8DT00566D10.1039/C8DT00566D ↗
6. 10.1021/ar00172a00510.1021/ar00172a005 ↗
7. 10.1002/anie.19952311110.1002/anie.199523111 ↗
8. 10.1039/b402150a10.1039/b402150a ↗
9. https://www.gpo.gov/fdsys/pkg/FR-2011-12-02/pdf/2011-31022.pdf.
10. https://www.fda.gov/media/99917/dowload.
11. https://www.fda.gov/downloads/Drugs/Guidances/UCM281764.pdf.
12. 10.1021/cg300294810.1021/cg3002948 ↗
13. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170467.pdf.
14. Seddon K. R. · 1999 · 53910.1007/978-94-015-9105-8 ↗
15. 10.1016/j.addr.2017.03.00310.1016/j.addr.2017.03.003 ↗
16. 10.1007/s41745-017-0026-410.1007/s41745-017-0026-4 ↗
17. 10.1016/j.xphs.2016.10.02110.1016/j.xphs.2016.10.021 ↗
18. 10.1557/mrs2006.20610.1557/mrs2006.206 ↗
19. 10.1021/ja035776p10.1021/ja035776p ↗
20. 10.1021/ja048114o10.1021/ja048114o ↗
21. 10.1021/acs.accounts.9b0021110.1021/acs.accounts.9b00211 ↗
22. 10.1107/S205252061900469410.1107/S2052520619004694 ↗
23. 10.1016/j.drudis.2018.11.02310.1016/j.drudis.2018.11.023 ↗
24. 10.1021/cg301212410.1021/cg3012124 ↗
25. 10.1039/C4CE00103F10.1039/C4CE00103F ↗
26. 10.1517/17425255.2014.94228110.1517/17425255.2014.942281 ↗
27. 10.1021/mp300169c10.1021/mp300169c ↗
28. 10.1021/acs.cgd.6b0090210.1021/acs.cgd.6b00902 ↗
29. 10.1039/c3ce41017j10.1039/c3ce41017j ↗
30. 10.1021/cg501864210.1021/cg5018642 ↗
31. 10.1039/c2ce25100k10.1039/c2ce25100k ↗
32. 10.1007/s11095-012-0709-510.1007/s11095-012-0709-5 ↗
33. 10.1002/adma.20090053310.1002/adma.200900533 ↗
34. 10.1039/C0CE00772B10.1039/C0CE00772B ↗
35. 10.1021/cg300887p10.1021/cg300887p ↗
36. 10.1021/cg400518w10.1021/cg400518w ↗
37. 10.1021/acs.cgd.5b0149110.1021/acs.cgd.5b01491 ↗
38. 10.1039/C7CC06992H10.1039/C7CC06992H ↗
39. 10.1248/cpb.c18-0081210.1248/cpb.c18-00812 ↗
40. 10.1107/S205225251400422910.1107/S2052252514004229 ↗
41. 10.1002/asia.20120020510.1002/asia.201200205 ↗
42. 10.1517/17425247.2013.74750810.1517/17425247.2013.747508 ↗
43. 10.1016/j.ijpharm.2007.05.00610.1016/j.ijpharm.2007.05.006 ↗
44. Aulton M. E. · 2017
45. Rowe R. C. · 2006 · 6
46. 10.1002/jps.2128010.1002/jps.21280 ↗
47. 10.1002/jps.2237210.1002/jps.22372 ↗
48. 10.1021/mp200043u10.1021/mp200043u ↗
49. 10.1007/s11095-013-1022-710.1007/s11095-013-1022-7 ↗
50. 10.1021/mp400176y10.1021/mp400176y ↗
51. 10.1021/cg200462g10.1021/cg200462g ↗
52. 10.1016/j.ejpb.2013.12.01610.1016/j.ejpb.2013.12.016 ↗
53. Matteo D’este, M.; Renier, D. Viscoelastic gels as novel fillers, U.S. Patent US0190644A1, 2012.
54. Brittain, H. G.; Felice, P. V. Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine, U.S. Patent US0190655A1, 2012.
55. 10.1016/S0015-0282(16)38045-110.1016/S0015-0282(16)38045-1 ↗
56. 10.1023/B:PHAM.0000016283.87709.a910.1023/B:PHAM.0000016283.87709.a9 ↗
57. 10.1016/j.ejps.2004.11.00510.1016/j.ejps.2004.11.005 ↗
58. 10.1055/s-2007-97960910.1055/s-2007-979609 ↗
59. Ullah M. · Pak. J. Pharm. Sci. · 2017 · 30 · 2139
60. 10.1016/j.ejpb.2009.04.01510.1016/j.ejpb.2009.04.015 ↗
61. 10.3109/03639045.2015.109628110.3109/03639045.2015.1096281 ↗
62. 10.1021/jm010153c10.1021/jm010153c ↗
63. Hageman, M. J.; He, X.; Kararli, T. T.; Mackin, L. A.; Miyake, P. J.; Rohrs, B. R.; Stefanski, K. J. Solid-state form of celecoxib having enhanced bioavailability. U.S. Patent US6964978B2, 2005.
64. Ferro, L. J., Polymorphic crystalline forms of celecoxib. U.S. Patent US7476744, 2000.
65. 10.1002/jps.2052210.1002/jps.20522 ↗
66. 10.1021/mp070010810.1021/mp0700108 ↗
67. 10.1212/WNL.43.8.160910.1212/WNL.43.8.1609 ↗
68. 10.1302/0301-620X.79B6.079095910.1302/0301-620X.79B6.0790959 ↗
69. 10.1111/j.2042-7158.2010.01189.x10.1111/j.2042-7158.2010.01189.x ↗
70. 10.1021/cg901232h10.1021/cg901232h ↗
71. 10.1021/cg401525610.1021/cg4015256 ↗
72. 10.1016/S0140-6736(10)61198-110.1016/S0140-6736(10)61198-1 ↗
73. 10.3390/cryst701001310.3390/cryst7010013 ↗
74. 10.1021/acs.molpharmaceut.7b0058710.1021/acs.molpharmaceut.7b00587 ↗
75. 10.1021/acs.molpharmaceut.8b0034010.1021/acs.molpharmaceut.8b00340 ↗
76. Qiu Y. · 2016
77. 10.1208/pt06024110.1208/pt060241 ↗
78. 10.1021/acs.cgd.6b0045810.1021/acs.cgd.6b00458 ↗
79. 10.1039/C4CC00159A10.1039/C4CC00159A ↗
80. 10.1016/j.toxlet.2003.07.00410.1016/j.toxlet.2003.07.004 ↗
81. Everything Added to Food in the United States (EAFUS); Food and Drug Administration, 2008.
82. 10.1021/cg900129f10.1021/cg900129f ↗
83. 10.1021/cg401339v10.1021/cg401339v ↗
84. 10.1021/acs.cgd.8b0093310.1021/acs.cgd.8b00933 ↗
85. 10.1039/c1ce05778b10.1039/c1ce05778b ↗
86. 10.1021/acs.cgd.5b0079810.1021/acs.cgd.5b00798 ↗
87. 10.1021/acs.cgd.6b0116010.1021/acs.cgd.6b01160 ↗
88. 10.1016/j.xphs.2017.04.01710.1016/j.xphs.2017.04.017 ↗
89. 10.1039/c3ce42008f10.1039/c3ce42008f ↗
90. 10.1107/S205322961800686110.1107/S2053229618006861 ↗
91. 10.1021/cg060742p10.1021/cg060742p ↗
92. 10.1002/anie.20070053410.1002/anie.200700534 ↗
93. 10.1021/mp100109a10.1021/mp100109a ↗
94. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2015.
95. https://www.astellas.com/en/news/11351.